Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Overview | Financials
Company Name | Madrigal Pharmaceuticals, Inc. |
Symbol | MDGL |
Currency | USD |
Price | 319.69 |
Market Cap | 6,972,566,776 |
Dividend Yield | 0% |
52-week-range | 168.25 - 368.29 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. William J. Sibold |
Website | https://www.madrigalpharma.com |
An error occurred while fetching data.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD